These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29115180)

  • 21. Rights, patents, markets and the global AIDS pandemic.
    Gathii JT
    Fla J Int Law; 2002; 14(2):261-352. PubMed ID: 16526139
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States.
    Frow EK; Brafman DA; Muldoon A; Krum L; Williams P; Becker B; Nelson JP; Pritchett A
    Stem Cell Reports; 2019 Aug; 13(2):247-253. PubMed ID: 31378670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulating the advertising and promotion of stem cell therapies.
    von Tigerstrom B
    Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Legal rights in transplantation: how adult stem cells may be defining and protecting the rights of donors.
    McIntire T
    Tenn Med; 2006 Apr; 99(4):29-32. PubMed ID: 16704128
    [No Abstract]   [Full Text] [Related]  

  • 25. Patenting life: biotechnology, intellectual property, and environmental ethics.
    Hettinger N
    Boston Coll Environ Aff Law Rev; 1995; 22(2):267-305. PubMed ID: 11656671
    [No Abstract]   [Full Text] [Related]  

  • 26. The dangers of unregulated stem-cell marketing.
    Mohammadi D
    Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714
    [No Abstract]   [Full Text] [Related]  

  • 27. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics.
    Ghinea N; Munsie M; Rudge C; Stewart C
    Regen Med; 2020 Feb; 15(2):1361-1369. PubMed ID: 32228372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Umbilical cord blood stem cells: my body makes them, but do I get to keep them? Analysis of the FDA proposed regulations and the impact on individual constitutional property rights.
    Fredrickson JK
    J Contemp Health Law Policy; 1998; 14(2):477-502. PubMed ID: 9693489
    [No Abstract]   [Full Text] [Related]  

  • 29. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.
    Turner L; Knoepfler P
    Cell Stem Cell; 2016 Aug; 19(2):154-157. PubMed ID: 27374789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 31. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA issues concerning conflicts of interest.
    Kurt TL
    IRB; 1990; 12(5):6-9. PubMed ID: 11654003
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 34. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.
    Knoepfler PS; Turner LG
    Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA regulation of stem-cell-based therapies.
    Halme DG; Kessler DA
    N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899
    [No Abstract]   [Full Text] [Related]  

  • 36. How should we think about clinical data ownership?
    Ballantyne A
    J Med Ethics; 2020 May; 46(5):289-294. PubMed ID: 31911499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oversight for clinical uses of autologous adult stem cells: lessons from international regulations.
    Lysaght T; Kerridge I; Sipp D; Porter G; Capps BJ
    Cell Stem Cell; 2013 Dec; 13(6):647-51. PubMed ID: 24315438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. My body, my body parts, my property?
    Beyleveld D; Brownsword R
    Health Care Anal; 2000; 8(2):87-99. PubMed ID: 11183448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA scrutinizes human stem cell therapies.
    Fox JL
    Nat Biotechnol; 2008 Jun; 26(6):598-9. PubMed ID: 18536668
    [No Abstract]   [Full Text] [Related]  

  • 40. Regulatory loophole enables unproven autologous cell therapies to thrive in Australia.
    Munsie M; Pera M
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():34-8. PubMed ID: 25457959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.